Neoadjuvant FOLFIRINOX and chemoradiation have been utilized to downstage borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC). Whether neoadjuvant therapy-induced tumor immune response contributes to the improved survival is unknown. Therefore, we evaluated whether neoadjuvant therapy induces an immune response towards PDAC.

中文翻译：

---

新辅助治疗胰腺导管腺癌患者的肿瘤微环境免疫反应。

新辅助FOLFIRINOX和化学放疗已用于降低界线和局部晚期胰腺导管腺癌（PDAC）的水平。新辅助疗法诱导的肿瘤免疫反应是否有助于改善生存率尚不清楚。因此，我们评估了新辅助疗法是否诱导针对PDAC的免疫反应。